Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: There is an unmet need for novel blood-based biomarkers that offer timely and accurate diagnostic and prognostic testing in inflammatory bowel diseases (IBD). We aimed to investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD. METHODS: A total of 171 patients (n=96 IBD,n=75 non-IBD) were prospectively recruited. A multi-biomarker model was derived using multivariable logistic regression analysis. Cox proportional hazards model was derived to assess the contribution of each variable to disease outcomes. RESULTS: SC correlated strongly with current biomarkers, including fecal calprotectin (FC) (n=50,ρ=0.50,P=1.6 × 10−4). SC was the strongest individual predictor of IBD diagnosis (odds ratio (OR): 9.37 (95% confidence interval (CI): 2.82–34.68),P=4.00 × 10−4) compared with other markers (C-reactive protein (CRP): OR 8.52 (95% CI: 2.75–28.63),P=2.80 × 10−4); albumin: OR 6.12 (95% CI: 1.82–22.16),P=0.004). In a subset of 50 patients with paired SC and FC, the area under receiver operating characteristic discriminating IBD from controls was better for FC than for SC (0.99, (95% CI 0.87–1.00) and 0.87 (95% CI:0.78–0.97), respectively;P=0.01). At follow-up (median 342 days; interquartile range: 88–563), SC predicted treatment escalation and/or surgery in IBD (hazard ratio (HR) 2.7, 95% CI: 1.1–4.9), in particular Crohn’s disease (CD) (HR 4.2, 95% CI 1.2–15.3). A model incorporating SC and either CRP or albumin has a positive likelihood ratio of 24.14 for IBD. At 1 year, our prognostic model can predict treatment escalation in IBD in 65% of cases (95% CI: 43–79%) and 80% (95% CI: 31–94%) in CD if ≥2 blood marker criteria are met. CONCLUSIONS: A diagnostic and prognostic model that combines SC and other blood-based biomarkers accurately predicts the inflammatory burden in IBD and has the potential to predict disease and its outcomes. Our data warrant further detailed exploration and validation in large multicenter cohorts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Lee, J. C., Lyons, P. A., McKinney, E. F., Sowerby, J. M., Carr, E. J., Bredin, F., Rickman, H. M., Ratlamwala, H., Hatton, A., Rayner, T. F., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59255 · Cited by 304
Research works printed but not linked: 45
- Kalla, 2014, Crohns disease., BMJ, 349, g6670, 10.1136/bmj.g6670 · DOI
- Ford, 2013, Ulcerative colitis., BMJ, 346, f432, 10.1136/bmj.f432 · DOI · Paper page
- Loftus, 2004, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences., Gastroenterology, 126, 1504, 10.1053/j.gastro.2004.01.063 · DOI · Paper page
- Kappelman, 2007, The prevalence and geographic distribution of Crohns disease and ulcerative colitis in the United States., Clin Gastroenterol Hepatol, 5, 1424, 10.1016/j.cgh.2007.07.012 · DOI · Paper page
- Kappelman, 2008, Direct health care costs of Crohns disease and ulcerative colitis in US children and adults., Gastroenterology, 135, 1907, 10.1053/j.gastro.2008.09.012 · DOI · Paper page
- Burisch, 2013, The burden of inflammatory bowel disease in Europe., J Crohns Colitis, 7, 322, 10.1016/j.crohns.2013.01.010 · DOI · Paper page
- Sands, 2015, Biomarkers of inflammation in inflammatory bowel disease., Gastroenterology, 149, 1275, 10.1053/j.gastro.2015.07.003 · DOI · Paper page
- Viennois, 2015, Biomarkers of inflammatory bowel disease: from classical laboratory tools to personalized medicine., Inflamm Bowel Dis, 21, 2467
- Kaiser, 2007, Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome., Gut, 56, 1706, 10.1136/gut.2006.113431 · DOI · Paper page
- van Rheenen, 2010, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis., BMJ, 341, c3369, 10.1136/bmj.c3369 · DOI · Paper page
- Lehmann, 2015, The role and utility of faecal markers in inflammatory bowel disease., Therap Adv Gastroenterol, 8, 23, 10.1177/1756283X14553384 · DOI
- Ho, 2009, Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis., Am J Gastroenterol, 104, 673
- Meuwis, 2013, Serum calprotectin as a biomarker for Crohns disease., J Crohns Colitis, 7, e678, 10.1016/j.crohns.2013.06.008 · DOI · Paper page
- Lasson, 2014, The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis., J Crohns Colitis, 9, 26
- Calafat, 2015, High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm., Bowel Dis, 21, 1072, 10.1097/MIB.0000000000000349 · DOI
- Reid, 2015, Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis., Am J Respir Crit Care Med, 191, 233, 10.1164/rccm.201407-1365LE · DOI
- Gray, 2010, Sputum and serum calprotectin are useful biomarkers during CF exacerbation., J Cyst Fibros, 9, 193, 10.1016/j.jcf.2010.01.005 · DOI · Paper page
- Abildtrup, 2015, Calprotectin as a biomarker for rheumatoid arthritis: a systematic review., J Rheumatol, 42, 760, 10.3899/jrheum.140628 · DOI
- Obry, 2014, Identification of S100A9 as biomarker of responsiveness to the methotrexateetanercept combination in rheumatoid arthritis using a proteomic approach., PLoS One, 9, e115800, 10.1371/journal.pone.0115800 · doi:10.1371/journal.pone.0115800
- Mariani, 2014, Serum calprotectin: review of its usefulness and validity in paediatric rheumatic diseases., Clin Exp Rheumatol, 33, 109
- Hammer, 2010, Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis., Ann Rheum Dis, 69, 150, 10.1136/ard.2008.103739 · DOI
- Boschetti, 2015, Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohns disease., Inflamm Bowel Dis, 21, 331, 10.1097/MIB.0000000000000273 · DOI
- Cury, 2013, Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis., Cell Immunol, 282, 66, 10.1016/j.cellimm.2013.04.004 · DOI
- Levine, 2011, Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification., Inflamm Bowel Dis, 17, 1314, 10.1002/ibd.21493 · DOI · Paper page
- Satsangi, 2006, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications., Gut, 55, 749, 10.1136/gut.2005.082909 · DOI · Paper page
- Averill, 2012, S100A8 and S100A9 in cardiovascular biology and disease., Arterioscler Thromb Vasc Biol, 32, 223, 10.1161/ATVBAHA.111.236927 · DOI · Paper page
- Ingersoll, 2010, Comparison of gene expression profiles between human and mouse monocyte subsets., Blood, 115, e10, 10.1182/blood-2009-07-235028 · DOI · Paper page
- Fagerhol, 2005, Increase in plasma calprotectin during long-distance running., Scand J Clin Lab Invest, 65, 211, 10.1080/00365510510013587 · DOI · Paper page
- Leach, 2007, Serum and mucosal S100 proteins, calprotectin (S100A8S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease., Scand J Gastroenterol, 42, 1321, 10.1080/00365520701416709 · DOI · Paper page
- Hare, 2014, P349 Serum calprotectin: a novel biomarker to predict outcome in acute severe ulcerative colitis?, J Crohns Colitis, 8, S210, 10.1016/S1873-9946(14)60469-4 · doi:10.1016/s1873-9946(14)60469-4
- Mor, 2005, Serum protein markers for early detection of ovarian cancer., Proc Natl Acad Sci USA, 102, 7677, 10.1073/pnas.0502178102 · DOI · Paper page
- Xiao, 2005, An approach to studying lung cancer-related proteins in human blood., Mol Cell Proteomics, 4, 1480, 10.1074/mcp.M500055-MCP200 · DOI
- Kennedy, 2015, Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years., J Crohns Colitis, 9, 41
- Mosli, 2015, C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis., Am J Gastroenterol, 110, 802, 10.1038/ajg.2015.120 · DOI · Paper page
- af Bjorkesten, 2012, Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohns disease., Scand J Gastroenterol, 47, 528, 10.3109/00365521.2012.660542 · DOI · Paper page
- DHaens, 2012, Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease., Inflamm Bowel Dis, 18, 2218, 10.1002/ibd.22917 · DOI · Paper page
- Schoepfer, 2010, Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohns disease (SES-CD) than CRP, blood leukocytes, and the CDAI., Am J Gastroenterol, 105, 162, 10.1038/ajg.2009.545 · DOI · Paper page
- Langhorst, 2008, Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices., Am J Gastroenterol, 103, 162, 10.1111/j.1572-0241.2007.01556.x · DOI · Paper page
- Beaugerie, 2006, Predictors of crohns disease., Gastroenterology, 130, 650, 10.1053/j.gastro.2005.12.019 · DOI · Paper page
- Boirivant, 1988, The clinical significance of serum C reactive protein levels in Crohns disease. Results of a prospective longitudinal study., J Clin Gastroenterol, 10, 401, 10.1097/00004836-198808000-00011 · DOI · Paper page
- Niewiadomski, 2015, Prospective population-based cohort of inflammatory bowel disease in the biologics era: disease course and predictors of severity., J Gastroenterol Hepatol, 30, 1346, 10.1111/jgh.12967 · DOI
- Henriksen, 2008, C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study., Gut, 57, 1518, 10.1136/gut.2007.146357 · DOI · Paper page
- Sandor Kiss, 2012, High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohns disease: a marker for patient classification?, Inflamm Bowel Dis, 18, 1647, 10.1002/ibd.21933 · DOI
- Costa, 2005, Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohns disease., Gut, 54, 364, 10.1136/gut.2004.043406 · DOI · Paper page
- Henderson, 2015, Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy., Inflamm Bowel Dis, 21, 596, 10.1097/MIB.0000000000000296 · DOI
Cited by
Calprotectin: from biomarker to biological function
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H., & Adolph, T. E. (2021) · Gut · doi:10.1136/gutjnl-2021-324855 · Cited by 500
Ulcerative colitis: Recent advances in the understanding of disease pathogenesis
Porter, R. J., Kalla, R., & Ho, G.-T. (2020) · F1000Research · doi:10.12688/f1000research.20805.1 · Cited by 300
Self-citationDumitrescu, L., Marta, D., Dănău, A., Lefter, A., Tulbă, D., Cozma, L., Manole, E., Gherghiceanu, M., Ceafalan, L. C., & Popescu, B. O. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689723 · Cited by 100
Serum biomarkers confirming stable remission in inflammatory bowel disease
Kessel, C., Lavric, M., Weinhage, T., Brueckner, M., de Roock, S., Däbritz, J., Weber, J., Vastert, S. J., & Foell, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-86251-w · Cited by 54
Okada, K., Itoh, H., & Ikemoto, M. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03470 · Cited by 15
Metadata
- Authors
- Kalla, R., Kennedy, N. A., Ventham, N. T., Boyapati, R. K., Adams, A. T., Nimmo, E. R., Visconti, M. R., Drummond, H., Ho, G.-T., Pattenden, R. J., Wilson, D. C., & Satsangi, J.
- Venue
- American Journal of Gastroenterology
- Published
- 2016-12
- Volume
- 111
- Issue
- 12
- Pages
- 1796-1805
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2513920879
- Cited by
- 124
- References
- 2
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. https://app.cochat.ai/papers/10.1038/ajg.2016.342
- The paper
- Kalla, R., Kennedy, N. A., Ventham, N. T., Boyapati, R. K., Adams, A. T., Nimmo, E. R., Visconti, M. R., Drummond, H., Ho, G.-T., Pattenden, R. J., Wilson, D. C., & Satsangi, J. (2016). Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2016.342
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.